CD8A and neoplasm: Post-treatment, mouse tumors were dissected, and CD8+ T cells isolated; rupatadine treatment reduced PD-1 expression in these cells, suggesting it may prevent CD8+ T cell exhaustion and boost anti-tumor immunity (Fig. 7I).